Posted on December 14th, 2009 by
Among postmenopausal women with advanced, estrogen receptor-positive breast cancer that has progressed or recurred after prior hormonal therapy, a higher dose of Faslodex® (fulvestrant) appears to be more effective than the standard dose. These results were presented at the 2009 San Antonio Breast Cancer Symposium.
Faslodex is a type of hormonal therapy known as an antiestrogen. It’s used for the treatment of metastatic, hormone receptor-positive breast cancer in postmenopausal women who experience cancer progression or recurrence after prior hormone therapy. A standard dose of Faslodex is 250 mg per month.
In order to assess the effects of a higher dose of Faslodex, researchers conducted a Phase III clinical trial known as CONFIRM (Comparison of Faslodex in Recurrent or Metastatic breast cancer). The study compared the standard dose of Faslodex to a higher dose (500 mg) among 736 women in 17 countries.
The results of the study suggested that a higher dose of Faslodex may be more active than the standard dose, and as well tolerated.
Reference: Di Leo A. CONFIRM: A Phase III, Randomized, Parallel-Group Trial Comparing Fulvestrant 250 mg vs Fulvestrant 500 mg in Postmenopausal Women with Estrogen Receptor-Positive Advanced Breast Cancer. Presented at the 32nd CTRC-AACR San Antonio Breast Cancer Symposium. December 9-13, 2009. San Antonio, TX. Abstract 25.
Copyright © 2010 CancerConsultants Breast Cancer Information Center. All Rights Reserved.
You must be logged-in to the site to post a comment.